

# Peroxynitrite-mediated oxidative protein modifications

Harry Ischiropoulos<sup>a,b,\*</sup>, Abu B. Al-Mehdi<sup>a</sup>

<sup>a</sup>Institute for Environmental Medicine, University of Pennsylvania, School of Medicine Philadelphia, Pennsylvania 19104, USA

<sup>b</sup>Department of Biochemistry and Biophysics, University of Pennsylvania, School of Medicine Philadelphia, Pennsylvania 19104, USA


Received 23 February 1995; revised version received 13 March 1995

**Abstract** Proteins are targets of reactive species and detection of oxidatively modified proteins is often used as an index of oxidative stress. Peroxynitrite is a strong oxidant formed by reaction of nitric oxide with superoxide. Using fatty acid-free bovine serum albumin as a model we examined peroxynitrite-mediated protein modifications. The reaction of protein with peroxynitrite resulted in the oxidation of tryptophan and cysteine, in the nitration of tyrosine, in the formation of dityrosine, in the production of 2,4 dinitrophenylhydrazine-reactive carbonyls and in protein fragmentation. The formation of 3-nitrotyrosine represents a specific peroxynitrite-mediated protein modification that is different from modifications mediated by reactive oxygen species.

**Key words:** Nitrotyrosine; Dityrosine; Protein carbonyl; Tryptophan oxidation; Protein fragmentation

## 1. Introduction

Peroxynitrite is formed by the reaction between two free radicals, nitric oxide and superoxide:



Peroxynitrite is not a free radical because the unpaired electrons of nitric oxide and superoxide are combined to form a new bond in peroxynitrite [1]. The second order rate constant of the reaction between nitric oxide and superoxide is  $6.7 \times 10^9 \text{ M}^{-1} \cdot \text{s}^{-1}$  [2]. The rate of the nitric oxide reaction with superoxide is approximately thirty times faster than the reaction of nitric oxide with oxyhemoglobin and three times faster than the reaction of superoxide with superoxide dismutase. Stimulated macrophages, neutrophils and endothelial cells have been shown to generate peroxynitrite [3–5] and recent data has provided evidence for in vivo formation of peroxynitrite in human atherosclerotic coronary vessels, in human acute lung injury and in chronic inflammation [6–9].

Peroxynitrite or its reactive intermediates can be toxic by reacting with several biological molecules. Peroxynitrite will oxidize unsaturated fatty acids in the absence of a metal catalyst to form thiobarbituric acid reactive substances and conjugated dienes [10], and to oxidize low molecular mass antioxidant molecules; glutathione, ascorbate and  $\alpha$ -tocopherol [11–13]. We have previously found that the spontaneous reaction of peroxynitrite with proteins results in the nitration of the ortho

positions of tyrosine residues to form nitrotyrosine [14]. The peroxynitrite-mediated nitration of tyrosine residues can also be catalyzed by  $\text{Fe}^{3+}$ -EDTA and Cu,Zn superoxide dismutase [15]. Nitrotyrosine has been detected in human pathologies [6–9] and is a useful marker for peroxynitrite detection. Here we examined additional protein modifications induced by peroxynitrite. We found that peroxynitrite induced the formation of protein carbonyls, the oxidation of tryptophan, tyrosine and cysteine residues and to cause protein fragmentation.

## 2. Materials and methods

### 2.1. Exposure of proteins to peroxynitrite

Peroxynitrite was synthesized from nitrite and  $\text{H}_2\text{O}_2$  as described previously [1]. The concentration of peroxynitrite was measured by the increase in absorbance at 302 nm ( $\epsilon_{302 \text{ nm}} = 1,670 \text{ M}^{-1} \cdot \text{cm}^{-1}$ ) in 1.2 N NaOH. Fatty acid free bovine serum albumin (BSA, Boehringer-Mannheim, Indianapolis, IN) at concentration of 4 mg/ml was reacted with chemically synthesized peroxynitrite in 100 mM potassium phosphate buffer, 100  $\mu\text{M}$  diethylenepentaacetic acid (DTPA), pH 7.4. The reaction was performed by placing a small aliquot of peroxynitrite (4–8  $\mu\text{l}$ ) in the side of a tube containing the BSA solution immediately followed by vigorous vortexing. To control for the potential effect of nitrite, nitrate and  $\text{H}_2\text{O}_2$  which are present in peroxynitrite [1], peroxynitrite was allowed to decompose for 5 min in the phosphate buffer before the addition of BSA (= 'reverse order'). To insure that peroxynitrite was decomposed, we measured the absorbance of peroxynitrite in 100 mM potassium phosphate buffer, 100  $\mu\text{M}$  DTPA, pH 7.4 at 302 nm. The absorbance at 302 nm of the decomposed peroxynitrite was the same as the buffer alone.

### 2.2. Lung perfusion

We utilized a blood-free isolated lung preparation [16]. All animal studies in this work have been approved by the Institutional Animal Care and Use Committee. Sprague–Dawley, adult, male rats (Charles River Breeding Laboratories, Kingston, NY) weighing 150–170 g were anesthetized and a tracheostomy was performed. The lungs were isolated and ventilated continuously with 95% oxygen/5% carbon dioxide throughout the duration of the experiments. The lungs were perfused at constant flow rate of 12 ml/min with a recirculating Krebs–Ringer bicarbonate buffer, pH = 7.4 containing 3% (w/v) fatty acid free-BSA and 10 mM glucose that was maintained at 37°C and equilibrated with the same gas mixture as the ventilation gas. Lungs were made ischemic by stopping the flow for 2 h while maintaining ventilation.

### 2.3. Analytical methods

After completion of the experiment the lungs were rapidly clamped frozen in liquid nitrogen. Lungs were homogenized under nitrogen in ice cold saline (1:10 tissue/medium) containing 0.01% butylated hydroxytoluene. 2,4 dinitrophenylhydrazine (DNPH)-reactive protein carbonyls in lung homogenates were analyzed as described previously [16]. To account for the presence of nitrotyrosine in the DNPH-reacted samples (DNPH and nitrotyrosine absorb maximally at 358 nm at acidic pH), all samples were divided to two aliquots that contained equal amount of protein. One aliquot was reacted with 0.05% (wt./vol.) DNPH (Aldrich, Milwaukee, WI) in 1 M HCl and the other with 1M HCl for one hour at 37°C. At the end of the incubation, the samples were passed through a Sephadex G-25 column using 50 mM phosphate buffer pH 6.0. The difference in absorbance at 358 nm (DNPH reacted-HCl reacted) was used to estimate the concentration of the DNPH-

\*Corresponding author. University of Pennsylvania Institute for Environmental Medicine, 1 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6068, USA. Fax: (1) (215) 898 0868. E-mail: hci@ifem.med.upenn.edu

reactive protein carbonyls using  $\epsilon_{358\text{ nm}} = 21,000\text{ M}^{-1}\cdot\text{cm}^{-1}$ . The yield of nitration was determined by measuring the absorbance at pH 11.5, ( $\epsilon_{430\text{ nm}} = 4,400\text{ M}^{-1}\cdot\text{cm}^{-1}$ ). Formation of dityrosine was monitored by the absorbance at 330 nm using the  $\epsilon_{330\text{ nm}} = 4,000\text{ M}^{-1}\cdot\text{cm}^{-1}$ . Oxidation of tryptophan was followed by the changes in fluorescence (excitation  $\lambda = 325\text{ nm}$  and emission  $\lambda = 410\text{ nm}$ ). The fatty acid free BSA samples were analyzed on 10% SDS gels and silver stained following the completion of the analysis. For amino acid analysis fatty acid free-BSA was reacted with peroxyntirite as described above and then hydrolyzed in vapor phase with 6 N HCl containing 1% phenol for 24 h at 110°C. The hydrolyzed samples were derivatized at room temperature with phenylisothiocyanate (PTC) and the derivitized amino acids were separated on a reverse phase Waters PicoTag column ( $3.9 \times 150\text{ mm}$ ). The PTC-amino acids in the hydrolysates were quantified by comparing their retention times and peak areas with a freshly derivitized standard mixture of amino acids containing authentic nitrotyrosine (Aldrich, Milwaukee, WI).

### 3. Results and discussion

Fatty acid free-BSA reacted with the same volume of different peroxyntirite concentrations in order to achieve an 10:1, 1:1, 1:5 and 1:10 ratio of protein to peroxyntirite. We used a solution of  $60.6\text{ }\mu\text{M}$  BSA in 100 mM potassium phosphate buffer to control for changes in pH because the chemically synthesized peroxyntirite is stored in 1.2 M NaOH. Since peroxyntirite decomposes in phosphate buffer with a pseudo first order rate of  $1.3\text{ s}^{-1}$  at 25°C and pH 7.4, a concentration of  $606\text{ }\mu\text{M}$  peroxyntirite – to give a ratio of 1:10 – will correspond approximately to a steady state exposure of  $8.5\text{ }\mu\text{M}$  for 1 min. Figure 1 shows that a molar ratio of 10:1 did not result in formation of protein carbonyls. However, reacting the protein at ratio of 1:1 or greater resulted in a concentration dependent increase of protein carbonyls. Similarly increasing the concentration of peroxyntirite to a molar ratio of 1:1, 1:5 and 1:10 resulted in the oxidation of 41, 74 and 77% ( $n = 3$ ) of the single free cysteine residue, respectively. The oxidation of the cysteine residue by peroxyntirite to form a protein-thiyl radical has been recently reported [17].

The reaction of protein with peroxyntirite resulted in a decrease of tryptophan fluorescence (Fig. 2A). The maximal tryptophan fluorescence of the unreacted protein was taken to represent  $121.2\text{ }\mu\text{M}$  because BSA contains two tryptophan residues. A 12, 29 and 45% oxidation of tryptophan residues was observed following the reaction of BSA with 1:1, 1:5 and 1:10 ratio of protein to peroxyntirite, respectively. The fluorescence




Fig. 1. DNPH-reactive carbonyl formation following treatment with peroxyntirite. Unreacted protein contained  $2.1 \pm 0.4\text{ nmol/mg}$  protein. The results represent 3 different preparation of fatty acid free-BSA and are expressed as mean  $\pm$  S.D.\* $P < 0.05$  compared to unreacted and reverse order of addition.




Fig. 2. Peroxyntirite-mediated modification of aromatic acid residues. (A) Loss of tryptophan fluorescence. (B) Formation of 3-nitrotyrosine. (C) Formation of dityrosine. Results represent 3–6 different preparation of fatty acid free-BSA and are expressed as mean  $\pm$  S.D.

of tryptophan is dependent on the integrity of the indole ring. Disruption of the ring by oxidation or N-nitration may be responsible for the loss of fluorescence. If N-nitration of the indole ring occurs then this may be another specific modification mediated by peroxyntirite that will be useful for in vivo detection. BSA contains 19 tyrosine residues and 1:1, 1:5 and 1:10 ratio of protein to peroxyntirite 0.12, 1.4 and 3.2% of the tyrosine residues were nitrated (Fig. 2B). The nitration of tyrosine residues was also confirmed by amino acid analysis. Based on the absorbance at 430 nm at alkaline pH the yield of nitrotyrosine of the peroxyntirite-treated BSA samples at 1:10 ratio was  $8.4 \pm 0.5\text{ }\mu\text{g/mg}$  of protein which was the same as the

amount of nitrotyrosine detected by amino acid analysis  $9.8 \pm 1.8 \mu\text{g}/\text{mg}$  ( $n = 3$ ) of protein. At 1:1, 1:5 and 1:10 ratio of protein to peroxynitrite 0.02, 0.09 and 0.11% of tyrosine residues were oxidized to dityrosine. The low yield of dityrosine formation is also confirmed by the absence of significant protein aggregation revealed by SDS-PAGE analysis (Fig. 3). However, the reaction of fatty acid free-BSA with peroxynitrite resulted in protein fragmentation as shown by the increase in band intensity of protein fragments with molecular weight lower than 66,000 (Figure 3). Furthermore, amino acid analysis of the protein reacted at ratio of 1:10 in addition to decrease in tyrosine residues also revealed a decreased recovery of more than 5%, as compared to control, of glutamic acid, histidine threonine and alanine (not shown). Histidine has been found to be sensitive to oxidation by reactive oxygen species as well as metal ion catalyzed oxidations [18]. Although not detected in this model system peroxynitrite has been shown to hydroxylate phenylalanine [19] and to oxidize methionine in  $\alpha$ 1-proteinase inhibitor [20].

Since the reaction of BSA with peroxynitrite resulted in the formation of DNPH-reactive protein carbonyls we examined the ability of peroxynitrite to form protein carbonyls in a preparation of lung homogenates. It was shown that ischemic injury to the lung results in an increase of protein carbonyls [16]. Lung




Fig. 3. Silver staining of SDS-PAGE analysis of peroxynitrite-treated samples. The same results were reproduced for at least 3 different protein preparations analyzing  $20 \mu\text{g}$  of protein per lane. Lane: 1, reverse order of addition at 1:10 molar ratio of protein to peroxynitrite; 2, protein reacted at 1:10 molar ratio; 3, protein reacted at 1:5 molar ratio; 4, unreacted protein; 5, unreacted protein reduced with  $\beta$ -mercaptoethanol; 6, protein reacted at 1:5 molar ratio; 7, protein reacted at 1:10 molar ratio; and 8, reverse order of addition at 1:10 molar ratio of protein to peroxynitrite.

Table 1  
DNPH-reactive protein carbonyls in lung homogenate

	DNPH-reactive protein carbonyls (nmol/mg of protein)
Control 2 h perfusion	$2.2 \pm 0.1$
2 h Ischemia	$6.9 \pm 0.4^*$
10 mM tert-Butyl hydroperoxide + $100 \mu\text{M Fe}^{2+}$	$7.4 \pm 0.5^*$
300 $\mu\text{M}$ peroxynitrite	$11.2 \pm 0.7^{***}$

Isolated rat lungs were perfused or made ischemic as described in methods. Lung homogenate aliquots containing 4–5 mg protein/ml were reacted with 10 mM tert-Butyl hydroperoxide plus  $100 \mu\text{M Fe}^{2+}$  for 30 min at  $37^\circ\text{C}$  and with peroxynitrite at room temperature. Data of three different lung homogenates is expressed as mean  $\pm$  SD, \*different than control, \*\*different than 10 mM tert-butyl hydroperoxide plus  $100 \mu\text{M Fe}^{2+}$ .

homogenates containing approximately 4 mg/ml protein were reacted with 300  $\mu\text{M}$  peroxynitrite. This treatment resulted in the formation of  $11.2 \pm 0.7$  nmol/mg of protein DNPH-reactive carbonyls that was significantly higher than control and than the levels of carbonyls formed after treatment of the same lung homogenates with 10 mM tert-butyl hydroperoxide in the presence of 100  $\mu\text{M}$  ferrous iron for 30 min at  $37^\circ\text{C}$  (Table 1). The levels of DNPH-reactive carbonyls formed by 300  $\mu\text{M}$  peroxynitrite which corresponds to an exposure of 4 mM for 1 min were also higher than the levels measured after 2 h of ischemia suggesting that peroxynitrite can contribute to in vivo protein carbonyl formation. Furthermore, we have recently found that the levels of protein carbonyls in ischemic rat lungs are significantly reduced by blockade of nitric oxide production [21]. Overall, peroxynitrite induced an array of protein modifications that arranged in order of magnitude include; cysteine oxidation, tryptophan oxidation, tyrosine nitration, formation of protein carbonyls, formation of dityrosine and protein fragmentation. The nitration of tyrosine residues and possibly of tryptophan are useful markers for detecting peroxynitrite in biological samples. Although the protein induced modifications of BSA by peroxynitrite can be considered to contribute to the antioxidant action of albumin in extracellular fluids [17], nitration of tyrosine residues and other peroxynitrite-mediated modifications inactivate important proteins such as Mn superoxide dismutase [14], surfactant protein A [22] and  $\alpha$ -1 proteinase inhibitor [20] and may contribute to toxicity in human disorders.

*Acknowledgments:* We thank Dr. Michael F. Beers for assistance with gel scanning and critical reading of the manuscript, Dr. William R. Abrams for assistance with the amino acid analysis, June Nelson and Daniel Duran for technical assistance. This work was supported by grants from the Pennsylvania Lung (HI, AA) and Southeastern Pennsylvania Heart Associations (HI). Dr. H. Ischiropoulos is a Parker B. Francis Fellow in Pulmonary Research and Dr. Abu Al-Mehdi is supported by a National Research Service Award in Respiratory Physiology.

## References

- [1] Beckman, J.S., Chen, J., Ischiropoulos, H. and Crow, J.P. (1994) *Methods Enzymol.* 233, 229–240.
- [2] Huie, R.E. and Padjama, S. (1993) *Free Rad. Res. Comm.* 18, 195–199.
- [3] Ischiropoulos, H., Zhu, L. and Beckman, J.S. (1992) *Arch Biochem. Biophys.* 298, 446–451.

- [4] Carreras, M.C., Pargament, G.A., Catz, S.D., Poderoso, J.J and Boveris, A. (1994) *FEBS Lett.* 341, 65–68.
- [5] Kooy, N.W. and Royall, J.A. (1994) *Arch. Biochem. Biophys.* 310, 352–359.
- [6] Beckman, J.S., Ye, Y.Z., Anderson, P.G., Chen, J., Accavitti, M.A., Tarpey, M.M. and White, C.R. (1994) *Biol. Chem. Hoppe-Seyler* 375, 81–88.
- [7] Haddad, I.Y., Pataki, G., Hu, P., Beckman, J.S. and Matalon, S. (1994) *J. Clin. Invest.* 94, 2407–2413.
- [8] Kooy, N.W., Royall, J.A., Ye, Y.Z., Kelly, D.R. and Beckman, J.S. (1995) *Am. J. Resp. Crit. Care Med.*, in press.
- [9] Kaur, H. and Halliwell, B. (1994) *FEBS Lett.* 350, 9–12.
- [10] Radi, R., Beckman, J.S., Bush, K.M. and Freeman, B.A. (1991) *Arch Biochem. Biophys.* 288, 481–487.
- [11] Kopenol, W.H., Moreno, J.J., Pryor, W.A., Ischiropoulos, H. and Beckman, J.S. (1992) *Chem. Res. Toxicol.* 5, 834–842.
- [12] Bartlett, D., Church, D.F., Bounds, P.L. and Koppenol, W.H. (1995) *Free Rad. Biol. Med.* 18, 85–92.
- [13] Hogg, N., Joseph, J. and Kalyanaram, B. (1994) *Arch Biochem. Biophys.* 314, 153–158.
- [14] Ischiropoulos, H., Zhu, L., Chen, J., Tsai, J.-H.M., Martin, J.C., Smith, C.D. and Beckman, J.S. (1992) *Arch Biochem. Biophys.* 298, 431–437.
- [15] Beckman, J.S., Ischiropoulos, H., Zhu, L., van der Woerd, M., Smith, C.D., Harrison, J., Martin, J.C. and Tsai, J.-H.M. (1992) *Arch Biochem. Biophys.* 298, 438–445.
- [16] Ayene, S.I., Al-Mehdi, A.B. and Fisher, A.B. (1993) *Arch. Biochem. Biophys.* 303, 307–312.
- [17] Gatti, R.M., Radi, R. and Augusto, O. (1994) *FEBS Lett.* 348, 287–290.
- [18] Stadman, E.R. (1990) *Free Radical Biol. Med.* 9, 315–325.
- [19] Van Der Vliet, A., O'Neill, C.A., Halliwell, B., Cross, C.E. and Kaur, H. (1994) *FEBS Lett.* 339, 89–92.
- [20] Moreno, J.J. and Pryor, W.A. (1992) *Chem. Res. Toxicol.* 5, 425–430.
- [21] Ischiropoulos, H., Al-Mehdi, A. and Fisher, A.B. (1994) *Am. J. Resp. Crit. Care Med.* 149, A 552.
- [22] Haddad, I.Y., Ischiropoulos, H., Holm, B.A., Beckman, J.S., Baker, J.R. and S. Matalon. (1993) *Am. J. Physiol.* 265, L555-L564.